- Chemotherapy is as beneficial for survival in patients with oncotype recurrence scores of 26-30 as with scores ≥31, according to a nationwide database analysis of patients with early, hormone receptor (HR)-positive/HER2− breast cancer.
Why this matters
- A 2018 pivotal study showed that chemotherapy conferred no extra benefit for women with scores of 11-25 vs ≥26, but did not address the benefit of scores in the 26-30 range.
- These results suggest that patients with scores in this range should receive chemotherapy.
- Retrospective US cohort study (n=17,197) of patients with early breast cancer and recurrence scores ≥26 in the National Cancer Database.
- 12,741 received chemotherapy.
- Funding: None disclosed.
- Median follow-up was 40.7 months.
- Regardless of chemotherapy status, vs lower scores, a recurrence score ≥31 was associated with worse mortality:
- HR, 1.75 (P<.001>
- In patients with scores of 26-30, chemotherapy was associated with better OS than not receiving chemotherapy:
- HR, 0.70 (P=.04).
- The extent of chemotherapy benefit was similar between patients with recurrence scores of:
- 26-30: HR, 0.59 (P<.001 and>
- ≥31: HR, 0.56 (P<.001>
- Retrospective, observational.
- Residual selection bias.